The largest PBMs are taking very different approaches to building their 2020 formularies, including maximizing rebates, focusing on multi-source brand exclusions and removing products that have experienced hyperinflation, benefits consultants say.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.